Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
New England Journal of Medicine2006Vol. 354(12), pp. 1264–1272
Citations Over TimeTop 1% of 2006 papers
Abstract
These data indicate that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events, even in populations with a high prevalence of non-lipid-related cardiovascular risk factors.
Related Papers
- → PCSK9 Antibodies for the Treatment of Hypercholesterolemia(2014)29 cited
- → Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience(2016)13 cited
- → Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia(2017)8 cited
- → The efficacy of anti-PCSK9 antibodies: Results from recent trials(2017)10 cited
- → Update on PCSK9 Inhibitors and New Therapies(2016)1 cited